Remix Therapeutics Appoints Mythili Koneru, MD, PhD, As Chief Medical Officer To Lead Clinical Development Of REM-422 And RNA-Targeting Pipeline

Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, announced today the appointment of Mythili Koneru, MD, PhD, as Chief Medical Officer. In this role, Dr. Koneru will oversee clinical development, medical strategy, and regulatory engagement as Remix advances its pipeline, including the first-in-class oral small molecule mRNA degrader, REM-422, through clinical development and regulatory milestones.

Pete Smith, PhD, Co-Founder and Chief Executive Officer of Remix, said, “Mythili’s extensive experience in advancing novel therapies in oncology through rigorous translational science and disciplined clinical execution will be critical as we move REM-422 and our broader pipeline forward. We are excited to have her lead our development team as we work to translate the potential of our RNA-targeting platform into meaningful medicines for patients.”

Dr. Koneru brings extensive expertise in drug development, with a strong track record of advancing novel therapeutics from early-stage research through later-stage clinical programs. She succeeds Chris Bowden, MD, who served as Chief Medical Officer at Remix until his retirement at the end of 2025.

“What attracted me to Remix was the opportunity to build on the encouraging clinical data for REM-422 in adenoid cystic carcinoma and help translate that momentum into meaningful progress for patients,” said Dr. Koneru. “Remix’s REMaster™ platform and scientific approach offer the potential to address high unmet medical needs by targeting mechanisms previously considered intractable. I look forward to designing rigorous, data-driven clinical programs that bring REM-422 and the broader pipeline to patients in need of new therapies.”

Dr. Koneru was most recently Chief Medical Officer at Legend Biotech, where she oversaw all clinical development and medical affairs activities. Previously, she served as Chief Medical Officer of Marker Therapeutics, leading the development of cellular therapies and peptide vaccines in its immuno-oncology portfolio. She also held positions at Eli Lilly, including Associate Vice President of Immuno-Oncology and Senior Medical Director of Early Phase Clinical Development, where she designed early-stage clinical trials for hematologic malignancies and solid tumors.

Dr. Koneru began her career as an oncology fellow in the laboratory of Dr. Renier Brentjens at Memorial Sloan-Kettering Cancer Center, where she worked on developing adoptive T cell therapies for both leukemia and solid tumors in early-phase clinical trials. She earned her bachelor’s degree in Biology from the University of Chicago, a doctorate in Biomedical Engineering from New York University, and her medical degree from Robert Wood Johnson Medical School.